Table 1.

Baseline and pathologic characteristics of 46 patients with HCC on the waiting list for LT. Variables are represented by median and interquartile range or by frequency and percentage, as appropriate.

No. of patients	46
Age (years)	60 (55–63)
No. of tumors	2 (1–3)
Tumor size	2.6 cm (2–4.6)
MELD score	9 (8–12)
No. of preoperative TACEs	1 (0–2)
Sex	n = 46
Male	41 (89.1%)
Female	5 (10.9%)
Etiology	n = 46
Viral (%)	18 (39.13%)
Non-viral (%)	18 (39.13%)
Mixed (viral + non-viral) (%)	10 (21.74%)
Child–Pugh score	n = 32
A	20 (62.5%)
B	9 (28.1%)
C	3 (9.4%)
Tumor size	n = 46
≤ 3 cm	28 (60.9%)
> 3 cm	18 (39.1%)
MELD score	n = 43
≤ 9	24 (55.8%)
> 9	19 (44.2%)
Preoperative TACES	n = 46
Yes	31 (67.4%)
No	15 (32.6%)
Vascular invasion	n = 31
Yes	4 (12.9%)
No	27 (87.1%)
Tumoral necrosis	n = 36
Yes	22 (61.1%)
No	14 (38.9%)
Recurrence	n = 35
Yes	4 (11.43%)
No	31 (88.57%)
Post-transplant death	n = 35
Yes	7 (20%)
No	28 (80%)

HCC hepatocellular carcinoma, MELD model for end-stage liver disease.